{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Champions Oncology, Inc.
Is Champions Oncology, Inc. technically bullish or bearish?
As of October 1, 2023, there is insufficient technical data to assess Champions Oncology, Inc.'s current stance.
Who are in the management team of Champions Oncology, Inc.?
As of March 2022, the management team of Champions Oncology, Inc. includes Chairman Joel Ackerman, CEO Dr. Ronnie Morris, Lead Independent Director Dr. David Sidransky, and several Independent Directors: Dr. Philip Breitfeld, Mr. Daniel Mendelson, Mr. Abba Poliakoff, and Mr. Scott Tobin. They oversee the company's strategic direction and operations.
What does Champions Oncology, Inc. do?
Champions Oncology, Inc. develops and sells technology solutions to personalize oncology drug development, with recent net sales of $17 million and a market cap of $111.31 million. The company operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
